Darolutamide is an investigational, non-steroidal androgen receptor antagonist.
News
Congenica raises £23.3m in series B funding round
The company was recently awarded a multi-year contract to be the exclusive provider of Diagnostic Decision Support Services for the world leading NHS Genomic Medicine Service
NHS, MSD collaborate to help eliminate hep C
The deal could help England become the first country in the world to eliminate hepatitis C.
AZ to accelerate drug discovery with BenevolentAI partnership
The companies will create a team of two scientists that will work side-by-side to combine AstraZeneca’s genomics, chemistry and clinical data.
NHS trusts to look more closely at research as a priority for improving care
The series of questions on research is relevant both to trusts with established research portfolios as well as those with less research activity.
RCGP wants NHS to be a “world leader in technology”
The college has released its new ‘tech manifesto’.
Lynparza use extended in EMA CHMP meeting
The positive opinion is based on data from the pivotal Phase III SOLO-1 trial.
71% of healthcare professionals believe obese people are not interested in losing weight
A contrasting 81% said they had made at least one serious weight-loss effort in the past.
GlaxoSmithKline wins Benlysta US label expansion for children
The approval marks the first medicine in the US approved for children with systemic lupus erythematosus.
Final chance to book tickets for the 2019 Clinical Researcher of the Year – The Americas gala dinner & awards ceremony!
This week is the final opportunity to book tickets for the gala dinner & awards ceremony which will be taking place on the 4th May at The Sheraton Hotel, Boston.
Dr Jim Golby reveals what makes the PharmaTimes Sales Awards such a unique challenge
The 2019 PharmaTimes Sales Awards have been enhanced to deliver a clinical, innovative and rigorous judging process to help further develop healthcare sales professionals.
Zynquista approved in EU for certain patients with type I diabetes
The approval is for adjunct use to insulin therapy to improve blood sugar control in adults.
Novo Nordisk’s Victoza found to cut blood sugar in children
The ELLIPSE trial is the first Phase III trial completed in over a decade in children and adolescents with type II diabetes.
Praulent gets FDA nod for heart attack and stroke
The approval was based on data from ODYSSEY OUTCOMES.
Pfizer’ Talzenna leads latest CHMP highlights
Thirteen medicines were recommended for approval at the committee’s April 2019 meeting.
